Improving the quality of life every day with innovative solutions.
Headquartered in Largo, Florida, BioDerm is one of the nation’s leading manufacturers of proprietary hydrocolloid products for urinary management, securement, infection control and skin protection. The company challenges accepted inferior standards of care by creating products that reduce infection rates, add comfort and reliability, and vastly improve quality of life. Our flagship products for male urinary incontinence are Men’s Liberty™ for the home and Men’s Liberty Acute™ for in-patient settings. Other product ranges include CathGrip® for securement and BioPlus™ and FreeDerm™ for skin protection.
BioDerm’s subsidiary company, Wound Care Resources™, has specialized in providing wound management DME supplies (and corresponding insurance billing) for patients with wounds since 2006. After becoming aware of the needs of the VAD community in 2010, WCR began billing patients’ insurance companies for surgical dressings needed for driveline exit site maintenance.
BioDerm, Inc. (“BioDerm” or the “Company”), a leading provider of disposable medical devices and wound care supplies to patients with chronic conditions, announced it has received a strategic investment from a Denver-based middle-market private equity firm, Mountaingate Capital (“Mountaingate”). With its new partner, BioDerm plans to accelerate its organic growth and pursue acquisitions that will expand its product and service offerings for patients.
Men’s Liberty, CathGrip, FreeDerm and KindKlamp are approved for Rx reimbursement. BioDerm is granted a Canadian patent for Men’s Liberty Acute, #3,058,756. Bioderm launches a new product – Faceplate Strip, a hydrocolloid strip designed to protect caregivers and patients from skin irritation due to excessive wear of PPE on the face.
BioDerm is issued patents for CathGrip line of products. Established retail presence for Men’s Liberty and ancillary products on Amazon. Gaet Tyranski appointed President & CEO; Gary Damkoehler retires from the management team, but remains Executive Chairman and Shawn Damkoehler appointed as Executive Vice Chairman. BioDerm completes acquisition of Wound Care Resources, Inc., a TN-based DME specializing in the provision of wound care supplies to VAD patients nationally. BioDerm is one of 50 Honorees for Grow FL Companies to Watch (#GFLCTW).
Reached 5 million Men’s Liberty™ external catheters sold with no reported attributable adverse events (per the FDA’s MAzUDE database); BioDerm in partnership with Medline joined together to launch Men’s Liberty Acute in the USA & Canada in Q1 2018 and the CathGrip® family of products in Q4 2018. BioDerm also recieved a new patent for Men’s Liberty™ and launched an improved and safer design to consumers.
BioDerm brings in new President, Gaet Tyranski, to accelerate growth in 2016 and beyond.
Launch of new products to the CathGrip securement line, PEGprotect and WingSeal. Established new international distribution agreements in Canada and the Middle East. Built on-site clinical support team for patients, sales reps and healthcare professionals.
BioDerm awarded Catheter Securement supplier agreement with the Premier Healthcare Alliance; Launch of BioDerm Penile Clamp; Acute Care sales force formed.
Reached 2 million Men’s Liberty™ catheters sold with no reported attributable adverse events (per the FDA’s MAUDE database); BioDerm brings on an independent sales team and national sales manager to drive growth; BioDerm awarded a U.S. Federal GSA Schedule contract under Schedule 65 II A – Medical Equipment and Supplies – identifying BioDerm as a “verified vendor” of urine collection products and accessories, for purchase by federal government agencies.
BioDerm rebrands as Men’s Liberty in the consumer market and Safe n’ Dry in the acute care market; Introduces new adjunct product lines: BioPlus+, FreeDerm and CathGrip.
Launching full scale, national direct-to-consumer sales campaign; Gary Damkoehler, formerly CEO of JSA Medical, takes over as CEO; BioDerm receives code verification from the Center for Medicare and Medicaid Services to support billing under HCPCS Code A4326.
BioDerm begins testing sales of a redesigned and improved Liberty catheter with an integral collection chamber; Medicare Part B reimbursement is granted under HCPCS Code A4326; First international sales begin to the UK and Netherlands.
Began initial testing of proposed direct-to-consumer sales models.
FDA rules the External Continence Device (ECD) as 510(k) exempt.
BioDerm, Inc. is founded as a research-only organization.